Posted on December 20, 2004 by Shanti Braford

It seems the FDA can’t quite make up it’s mind about Pfizer’s mega-drug, Celebrex. Is it harmful, or is it safe?

In an unusual move that reflects serious concerns about the new results, the agency asked the company to suspend its use of direct-to-consumer advertising and alter its marketing to doctors, as regulators and the company examine the data from the National Institutes of Health trial. The commitment was “open- ended,” said John Jenkins, director of the FDA’s office of new drugs.

More on CNN Money: FDA Asks Pfizer to Pull Back Marketing of Celebrex